Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients

Intervention Study of a Comprehensive Pulmonary Rehabilitation Program on Quality of Life and Prognosis in Patients With Pulmonary Arterial Hypertension

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06973382

Acronym

EPRQoL-PAH

Enrollment

Registered

2025-05-15

Start date

2025-05-20

Completion date

2027-10-31

Last updated

2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CTEPH, PAH

Brief summary

Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise. PH is a progressive and disabling disease, with studies showing its progression correlates with worsening symptoms and increased mortality. Even with targeted medications, the prognosis remains poor across PH subtypes, with PAH patients showing only a 49% 7-year survival rate. The 2022 ESC/ERS guidelines emphasize that PH management requires a comprehensive, multidisciplinary approach. Beyond pharmacological and surgical treatments, rehabilitation has demonstrated benefits in improving exercise capacity, quality of life, functional class, and peak oxygen consumption. However, research on specific and effective comprehensive pulmonary rehabilitation programs remains lacking.

Interventions

BEHAVIORALComprehensive Pulmonary Rehabilitation Program

Combined Aerobic + Resistance Training Program Mode: Cycle ergometry (stationary bicycle) Frequency: 3-5 sessions per week Program Duration: 12 weeks Session Structure: * 5-minute warm-up * Continuous or interval training (15-30 minutes) * 5-minute cool-downesistance Exercise Component Mode: Dumbbell exercises + cycle ergometry Frequency: 3 sessions per week Program Duration: 12 weeks Session Structure: * 5-minute warm-up * Training session (10-20 minutes) * 5-minute cool-down

BEHAVIORALStandard Pulmonary Rehabilitation

xercise Components: Aerobic Exercise Mode: Walking or jogging Resistance Exercise Mode: Elastic bands or dumbbells Training Parameters: Session Duration: ≥35 minutes (combined aerobic + resistance) Frequency: 3-5 sessions per week Program Duration: 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Confirmed PH Diagnosis: Right heart catheterization-confirmed pulmonary hypertension Meets 2022 ESC/ERS Guidelines diagnostic criteria for: * Group 1 (PAH) or * Group 4 (CTEPH/other pulmonary artery obstructions) Stabilized Treatment Status: Group 1 (PAH): Received ≥3 months of targeted drug therapy Group 4 (CTEPH): Completed ≥6 sessions of BPA\* or reached therapeutic endpoint Functional Capacity: WHO Functional Class I-III Age: ≥18 years Consent: Willing to provide written informed consent -

Exclusion criteria

Physical Limitations: Unable to perform pulmonary rehabilitation exercises due to disability or congenital malformations Cardiopulmonary Testing Contraindications: Medically unfit to complete CPET (cardiopulmonary exercise testing) after evaluation Poor Compliance: History of non-adherence making protocol completion unlikely Life Expectancy: Prognosis ≤1 year \-

Design outcomes

Primary

Measure	Time frame
6MWD	12week

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026